Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics Holdings, Inc. (SENS) announced the enrollment of its first pediatric participant in the ENHANCE clinical trial for the Eversense® 365-day continuous glucose monitoring (CGM) system. This pivotal trial, directed by Dr. Timothy Bailey at AMCR Institute, aims to evaluate the system's accuracy and safety over one year, with a focus on extending its benefits to young diabetes patients aged 14 to 18. With previous data from over 165 adult subjects and an expected completion of the last patient visit in Q3 2023, successful trial outcomes could bolster the company's position in the diabetes management market. Senseonics emphasizes the device's unique benefits, allowing pediatric users to remove transmitters during activities, enhancing their quality of life while managing diabetes.
Senseonics Holdings, Inc. (NYSE American: SENS) has granted equity awards to 13 new non-executive employees under its 2019 Inducement Plan. On April 4, 2023, the Compensation Committee approved non-qualified stock options for 200,000 shares and restricted stock units for 250,000 shares, with an exercise price of $0.5951 per share. The options and units will vest over time, contingent on continuous employment. Senseonics focuses on developing innovative long-term implantable glucose monitoring systems aimed at improving diabetes management.
Senseonics Holdings, Inc. (SENS) reported financial results for Q4 and full year 2022, revealing a total revenue of $16.4 million for 2022, up from $13.7 million in 2021. Notably, Q4 2022 revenue reached $5.6 million, marking a rise from $4.0 million in Q4 2021. Gross profit for the full year was $2.7 million, a significant improvement from a gross loss of $0.8 million. The company achieved a net income of $142.1 million in 2022, compared to a net loss of $302.5 million the previous year. Senseonics also anticipates revenue growth for 2023, projecting a range of $20 million to $24 million, indicating an increase of 22% to 46% compared to 2022.
Senseonics (AMEX:SENS) will release its fourth quarter and full year 2022 financial results after market close on March 15, 2023. A joint virtual event with PHC Holdings and Ascensia Diabetes Care will take place on the same day at 6:30 pm ET, featuring presentations from executives including Tim Goodnow and Rick Sullivan. They will discuss the Eversense technology portfolio, commercial partnerships, and provide financial guidance. The webcast will be accessible on Senseonics' website under “Investor Relations” for future reference.
Senseonics Holdings, Inc. (NYSE American: SENS) announced it granted equity to 10 new non-executive employees under its 2019 Inducement Plan. On January 5, 2023, the Compensation Committee awarded non-qualified stock options totaling 115,000 shares at an exercise price of $1.02, reflecting the closing share price on the grant date. The options will vest 25% on the first anniversary of employment and monthly thereafter over three years, contingent on continued service. Senseonics specializes in long-term implantable continuous glucose monitoring systems for diabetes management.
Senseonics Holdings, Inc. (SENS), a leader in long-term implantable continuous glucose monitoring systems, has announced their participation in the Stifel Healthcare Conference in New York, NY. Scheduled for Tuesday, November 15, 2022, at 11:30am ET, management will engage in one-on-one meetings post-presentation. A live and recorded webcast will be accessible through a provided link.
Senseonics aims to enhance the lives of those with diabetes through its innovative glucose management technology, including the Eversense CGM system that continuously transmits glucose data to users' mobile devices.
Senseonics Holdings, Inc. (NYSE American: SENS) reported its financial results for the quarter ended September 30, 2022, generating $4.6 million in revenue, up from $3.5 million in Q3 2021. U.S. revenue rose to $1.9 million, while international revenue saw a decline to $2.7 million. The company experienced a net loss of $60.4 million compared to a net income of $42.9 million in the previous year, largely due to non-cash accounting adjustments. Senseonics updated its full-year revenue outlook to $15.0 million to $17.0 million from a previous range of $14.0 million to $18.0 million.
Senseonics Holdings, Inc. (SENS) announces its collaboration with the Nurse Practitioner Group (NPG) to enhance access to the Eversense® E3 Continuous Glucose Monitoring (CGM) System. The initiative aims to provide convenient at-home and in-office insertion options for diabetes patients. The first Eversense E3 sensor was successfully inserted in Florida, with plans for expansion across the U.S. This partnership will facilitate certified NPG providers to perform Eversense procedures, thereby broadening clinician reach and improving patient experiences.
Senseonics Holdings, Inc. (NYSE American: SENS) has announced it will release its third quarter 2022 financial results after market close on November 8, 2022. The management will host a conference call at 4:30 p.m. ET on the same day to discuss the company's performance. Senseonics focuses on long-term, implantable continuous glucose monitoring (CGM) systems aimed at the diabetes community, with products like Eversense® and Eversense® XL providing real-time glucose data through a small sensor under the skin.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
